About Arf-GAP with dual PH domain-containing protein 1
Arf-GAP with dual PH domain-containing protein 1 (ADAP1) is a protein
from Homo sapiens identified by UniProt accession
O75689, 374 residues long.
MolForge cross-references it against 0 known binders and
60 disease associations.
Target properties
| Protein name | Arf-GAP with dual PH domain-containing protein 1 |
| UniProt accession | O75689 |
| Gene | ADAP1 |
| Organism | Homo sapiens |
| Length | 374 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (60)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.37
- lymphocyte percentage of leukocytes · score 0.34
- apolipoprotein A 1 measurement · score 0.31
- platelet component distribution width · score 0.23
- neurodegenerative disease · score 0.21
- high density lipoprotein cholesterol measurement · score 0.21
- platelet count · score 0.18
- alkaline phosphatase measurement · score 0.16
- monocyte count · score 0.15
- mean platelet volume · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75689-F1 | alphafold | PREDICTED | 95.94 | — |
Amino-acid sequence (374 residues)
MAKERRRAVL ELLQRPGNAR CADCGAPDPD WASYTLGVFI CLSCSGIHRN IPQVSKVKSV RLDAWEEAQV EFMASHGNDA ARARFESKVP SFYYRPTPSD CQLLREQWIR AKYERQEFIY PEKQEPYSAG YREGFLWKRG RDNGQFLSRK FVLTEREGAL KYFNRNDAKE PKAVMKIEHL NATFQPAKIG HPHGLQVTYL KDNSTRNIFI YHEDGKEIVD WFNALRAARF HYLQVAFPGA GDADLVPKLS RNYLKEGYME KTGPKQTEGF RKRWFTMDDR RLMYFKDPLD AFARGEVFIG SKESGYTVLH GFPPSTQGHH WPHGITIVTP DRKFLFACET ESDQREWVAA FQKAVDRPML PQEYAVEAHF KHKP
Explore Arf-GAP with dual PH domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets